The COVID 19 Project tests the hypotheses that citizens, provided with information and tools can be trusted to address the complex problems in their community and nationally.
Get Involved
TAKE PART IN OUR EFFORT
Citizens and civil society organizations interested in supporting and joining the COVID 19 Project are welcome.
Join us for our online event at the occasion of the beginning of the Citizen Commission (Details to come)
Areas of Therapeutic/ Clinical Research:
-
Prevention: Vacines
-
Testing
-
Antivirals
-
Immuneregulators
-
Host-directed therapies
-
Supportive treatment
References:
Clinical
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review JAMA April 13th, 2020
Popular
The Quest for a Pandemic Pill Can we prepare antivirals to combat the next global crisis? The NewYorker April 6, 2020
We now have a choice between two futures. In the first scenario, we continue as usual, relying on the big pharmaceutical companies, hoping that some potential treatment for COVID-19 will make it through clinical trials, and that other technologies for detection, testing, and protection will emerge.
In the second possible future, we would acknowledge that the current system – in which private monopolies profit from knowledge that is largely produced by public institutions – is not fit for purpose.
Research: The Coronavirus (SARS-CoV-2) and the COVID-19 Pandemic
This section focuses on research associated with the Coronavirus (SARS-CoV-2) and the COVID-19 Pandemic
Goal:
-
Provide information about current research of Coronavirus (SARS-CoV-2),
-
Explore gaps in existing knowledge
-
Suggest ideas for research
-
Develop a crowdsourced network
Overall Approach:
It is extraordinarily difficult to conduct randomized, controlled trials in the setting of an outbreak. Such trials are logistically complex, take a substantial amount of time to launch, and raise complex ethical considerations in the context of a rapidly spreading, highly fatal disease. But they provide the best data to guide treatment. Trials are particularly difficult to plan and execute during an epidemic in which shifting background care has a potential benefit with regard to outcomes. Using ethical considerations the justification and feasibility of a randomized design has been called into question.
Currently, there are many trials are underway to find the best interventions along the natural course of COVID 19, from vaccines to target the virus, enhancing the immune function,
treating the symptoms caused by the virus and related nonpharmacologic treatment.
The current circumstances of the deepening pandemic provide an opportunity for a different way to study the risks and potential for external cannabinoids (plant-based phytocannabinoids) in the severely ill individual suffering from COVID 19. The current reality calls for experimentations using different approaches and guidelines for clinical trials. WHO launches a multinational trial to jumpstart the search for coronavirus drugs, the US Federal Government “slashed red tape” to expand trials. A recent infogram summarized current research on COVID 19.
Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primer and Probe Information
-
ClinicalTrials.gov: Federally-funded clinical studies related to COVID-19
-
WHO Trial Registry Network: COVID-19 studies from the ICTRP database
-
WHO R&D Blueprint Informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection Geneva, Switzerland, 24 January 2020
-
Coronavirus disease 2019 (COVID-19)situation report – 52. March 12, 2020
March 13, 2020: WHO to launch a multinational trial to jumpstart the search for coronavirus drugs